keyword
MENU ▼
Read by QxMD icon Read
search

Macular edema anti-VEGF

keyword
https://www.readbyqxmd.com/read/29316563/visual-outcomes-based-on-early-response-to-anti-vascular-endothelial-growth-factor-treatment-for-diabetic-macular-edema
#1
Yoshito Koyanagi, Shigeo Yoshida, Yoshiyuki Kobayashi, Yuki Kubo, Takahito Nakama, Keijiro Ishikawa, Shintaro Nakao, Toshio Hisatomi, Yasuhiro Ikeda, Yuji Oshima, Tatsuro Ishibashi, Koh-Hei Sonoda
OBJECTIVE: To examine the relationship between early response to anti-vascular endothelial growth factor (VEGF) treatment and visual prognosis. METHODS: We retrospectively separated 20 patients with persistent diabetic macular edema (DME) into two responder status groups based on the reduction of central macular thickness (CMT) from baseline to month 3: a delayed responder group (DRG) (≤25% CMT reduction, n = 11) and an immediate responder group (IRG) (>25% CMT reduction, n = 14)...
January 9, 2018: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/29280367/intravitreal-bevacizumab-in-diabetic-retinopathy-recommendations-from-the-pan-american-collaborative-retina-study-group-pacores-the-2016-knobloch-lecture
#2
J Fernando Arevalo, T Y Alvin Liu
The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus on the efficacy of intravitreal bevacizumab in the management of diabetic macular edema and proliferative diabetic retinopathy. We will also discuss the use of intravitreal bevacizumab as a preoperative, adjuvant therapy before vitrectomy for proliferative diabetic retinopathy...
December 27, 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/29211782/generative-mathematical-modelling-to-demonstrate-virtual-simulations-of-neovascular-age-related-macular-degeneration
#3
David Hoyle, Tariq Mehmood Aslam
PURPOSE: To develop a generative mathematical model of wet age-related macular degeneration (AMD) and model the impact of injections of anti-vascular endothelial growth factor to virtual patients with the condition. METHODS: We isolated key pathophysiological components of macular degeneration in terms of macular edema development and response to anti-vascular endothelial growth factor (VEGF) agents. We developed mathematical models for each of these components using constants determined from published biological experimentation...
2017: PloS One
https://www.readbyqxmd.com/read/29210010/management-of-diabetic-macular-edema-in-japan-a-review-and-expert-opinion
#4
REVIEW
Hiroko Terasaki, Yuichiro Ogura, Shigehiko Kitano, Taiji Sakamoto, Toshinori Murata, Akito Hirakata, Tatsuro Ishibashi
Diabetic retinopathy is a frequent cause of visual impairment in working-age adults (≥ 30 years) and in Japan is most commonly observed in those aged 50-69 years. Diabetic macular edema (DME) is one of the main causes of vision disturbance in diabetic retinopathy, which is a clinically significant microvascular complication of diabetes. Anti-vascular endothelial growth factor (VEGF) therapy is becoming the mainstay of treatment for DME. However, to achieve sustained long-term improvement in visual acuity, conventional laser photocoagulation, vitrectomy and steroid therapy are also expected to play a role in the treatment of DME...
December 5, 2017: Japanese Journal of Ophthalmology
https://www.readbyqxmd.com/read/29204993/update-on-the-use-of-anti-vegf-intravitreal-therapies-for-retinal-vein-occlusions
#5
REVIEW
Yi Jiang, William F Mieler
The use of anti-vascular endothelial growth factor (VEGF) therapy in ophthalmology has profoundly changed our management and treatment of conditions such as cystoid macular edema, diabetic macular edema, choroidal neovascularization, and other proliferative retinopathies. Although initially used for the treatment of choroidal neovascularization in neovascular age-related macular degeneration, their application has spread rapidly for other indications as their outcomes have often outperformed previously existing treatments...
November 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/29204069/the-role-of-focal-laser-in-the-anti-vascular-endothelial-growth-factor-era
#6
REVIEW
Jason N Crosson, Lauren Mason, John O Mason
Introduction: To review important studies examining focal laser for diabetic macular edema (DME), to examine real-world data regarding actual treatments patients are receiving, to present long-term visual outcomes in real-world practice, and to suggest an evidence-based approach for the use of focal laser. Methods: This study is a review of landmark studies evaluating focal laser and pharmacologic therapy for DME. In addition, the authors include a retrospective review of 102 consecutive eyes of 53 patients in our practice setting in rural Alabama...
2017: Ophthalmology and Eye Diseases
https://www.readbyqxmd.com/read/29180844/vitreoretinal-interface-abnormalities-in-diabetic-macular-edema-and-effectiveness-of-anti-vegf-therapy-an-optical-coherence-tomography-study
#7
Alexei N Kulikov, Sergei V Sosnovskii, Roman D Berezin, Dmitrii S Maltsev, Dzhambulat H Oskanov, Nikolai A Gribanov
Purpose: To study vitreoretinal interface (VRI) abnormalities in diabetic macular edema (DME) and the influence of these on the effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) therapy. Methods: VRI status and central retinal thickness (CRT) were evaluated using line and 3D-reference scans obtained using spectral domain-optical coherence tomography RTVue-100 before and 1 month after intravitreal anti-VEGF injection (IVI). VRI status was categorized into five subgroups: normal VRI, retinal surface wrinkling associated with the eccentric epiretinal membrane (ERM), ERM involving the macular center, vitreomacular adhesion (VMA), and vitreomacular traction (VMT)...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/29179221/-vitreomacular-traction-following-anti-vegf-therapy-two-cases
#8
Sophie Helene Wallraf, Kristina Markova, Christos Haritoglou
Vitreomacular traction syndrome (VMTS) is defined as an incomplete or anomalous posterior vitreous detachment resulting in tractional forces at the macular region. In the context of anti-VEGF therapy, the formation of vitreoretinal traction has mainly been reported as a potential complication of VEGF inhibition in ischemic proliferative retinal disease, such as proliferative diabetic retinopathy. In this report, we present two patients who developed VMTS during anti-VEGF therapy for exudative age-related macular degeneration and diabetic macular edema...
November 27, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/29137019/optical-coherence-tomography-angiography-in-patients-with-diabetic-retinopathy-treated-with-anti-vegf-intravitreal-injections-case-report
#9
Katarzyna Michalska-Małecka, Anna Heinke Knudsen
PURPOSE: To present optical coherence tomography angiography (OCTA) features in patients with diabetic retinopathy (DR) at the baseline and in response to treatment with anti-VEGF intravitreal injections. To investigate the role of OCTA in management of patients with DR. METHODS: Retrospective case series showing primary outcomes of 3 patients with DR and diabetic macular edema. Patients were injected intravitreally a loading phase of 3 monthly 2.0 mg aflibercept, followed by 2 injections bimonthly (5 injections in total)...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29127949/effect-of-adding-dexamethasone-to-continued-ranibizumab-treatment-in-patients-with-persistent-diabetic-macular-edema-a-drcr-network-phase-2-randomized-clinical-trial
#10
Raj K Maturi, Adam R Glassman, Danni Liu, Roy W Beck, Abdhish R Bhavsar, Neil M Bressler, Lee M Jampol, Michele Melia, Omar S Punjabi, Hani Salehi-Had, Jennifer K Sun
Importance: Some eyes have persistent diabetic macular edema (DME) following anti-vascular endothelial growth factor (anti-VEGF) therapy for DME. Subsequently adding intravitreous corticosteroids to the treatment regimen might result in better outcomes than continued anti-VEGF therapy alone. Objective: To compare continued intravitreous ranibizumab alone with ranibizumab plus intravitreous dexamethasone implant in eyes with persistent DME. Design, Setting, and Participants: Phase 2 multicenter randomized clinical trial conducted at 40 US sites in 129 eyes from 116 adults with diabetes between February 2014 and December 2016...
November 11, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/29120158/diabetic-macular-edema-traditional-and-novel-treatment
#11
Martina Tomić, Romano Vrabec, Tamara Poljičanin, Spomenka Ljubić, Lea Duvnjak
Diabetes is one of the leading public health problems worldwide. Diabetic macular edema (DME) is the main cause of vision loss in patients with diabetes. Ideal metabolic control of diabetes is the primary goal of treatment and the basic way of preventing and stopping the progression of DME. Although laser photocoagulation has been the standard treatment of DME for nearly three decades, superior outcomes can be achieved with novel, intravitreal anti-VEGF and steroid therapy. Novel treatment option for DME depends on visual acuity and location/extent of macular thickening based on optical coherence tomography scans...
March 2017: Acta Clinica Croatica
https://www.readbyqxmd.com/read/29120156/diabetic-macular-edema-traditional-and-novel-treatment
#12
Martina Tomić, Romano Vrabec, Tamara Poljičanin, Spomenka Ljubić, Lea Duvnjak
Diabetes is one of the leading public health problems worldwide. Diabetic macular edema (DME) is the main cause of vision loss in patients with diabetes. Ideal metabolic control of diabetes is the primary goal of treatment and the basic way of preventing and stopping the progression of DME. Although laser photocoagulation has been the standard treatment of DME for nearly three decades, superior outcomes can be achieved with novel, intravitreal anti-VEGF and steroid therapy. Novel treatment option for DME depends on visual acuity and location/extent of macular thickening based on optical coherence tomography scans...
March 2017: Acta Clinica Croatica
https://www.readbyqxmd.com/read/29110201/dexamethasone-intravitreal-implant-in-diabetic-macular-edema-real-life-data-from-a-prospective-study-and-predictive-factors-for-visual-outcome
#13
Irini Chatziralli, Panagiotis Theodossiadis, Efstratios Parikakis, Eleni Dimitriou, Tina Xirou, George Theodossiadis, Stamatina Α Kabanarou
INTRODUCTION: The purpose of the study was to evaluate the long-term anatomical and functional outcomes in patients with diabetic macular edema (DME) treated with intravitreal dexamethasone implant and to determine the predictive factors for the final visual outcome. METHODS: The study included 54 patients with DME refractory to previous antivascular endothelial growth factor (anti-VEGF) who were treated with intravitreal dexamethasone implant. Predictive factors for visual outcome were assessed...
December 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29109896/outcomes-of-intravitreal-dexamethasone-implant-in-the-treatment-of-recalcitrant-diabetic-macular-edema
#14
Dorukcan Akıncıoğlu, Murat Küçükevcilioğlu, Ali Hakan Durukan, Seçkin Aykaş, Önder Ayyıldız, Fazıl Cüneyt Erdurman
Objectives: To investigate the efficacy and safety of intravitreal dexamethasone (OZURDEX®) implantation in patients with recalcitrant diabetic macular edema. Materials and Methods: This is a retrospective non-randomized study of patients who underwent intravitreal dexamethasone implantation for recalcitrant diabetic macular edema. Main outcome measures included changes in best corrected visual acuity (BCVA), central macular thickness (CMT), and incidence of ocular side effects...
October 2017: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/29104958/prediction-of-anti-vegf-response-in-diabetic-macular-edema-after-1-injection
#15
Ankoor R Shah, Yoshihiro Yonekawa, Bozho Todorich, Lily Van Laere, Rehan Hussain, Maria A Woodward, Ashkan M Abbey, Jeremy D Wolfe
Purpose: With multiple anti-vascular endothelial growth factor and steroid therapies available for diabetic macular edema (DME), there is a need for early determination of the best treatment for a particular patient to prevent irreversible vision loss from chronic DME. In this study, we classify patients as responders or non-responders to anti-vascular endothelial growth factor (VEGF) monotherapy in the treatment of DME after a single anti-VEGF injection. Methods: The study was designed as a single center, retrospective, interventional case series...
May 2017: Journal of vitreoretinal diseases
https://www.readbyqxmd.com/read/29091878/subthreshold-diode-micropulse-laser-versus-conventional-laser-photocoagulation-monotherapy-or-combined-with-anti-vegf-therapy-for-diabetic-macular-edema-a-bayesian-network-meta-analysis
#16
REVIEW
Ying Wu, Pu Ai, Zisheng Ai, Guotong Xu
AIMS: To assess the effects of laser photocoagulation as monotherapy or adjuvant therapy for the treatment of DME. METHODS: A search of the Cochrane Library, Pubmed, Embase, and the clinicaltrial.gov registry for randomized clinical trials comparing any two treatments of interest (SDMLP monotherapy, CLP monotherapy, CLP plus anti-VEGF therapy) was performed. Data were collected and pooled by Bayesian network meta-analyses which accounts for both direct and indirect comparisons...
October 26, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29091350/novel-strategy-for-screening-of-diabetic-retinopathy
#17
Hitoshi Takagi
Diabetic retinopathy is the most common cause of blindness in adults. Visual deficiency is mainly caused from clinically significant macular edema or vision-threatening proliferative diabetic retinopathy. Recent advances in the treatment modalities such as laser photocoagulation or with intraocular glucocorticoids or anti-vascular endothelial growth factor (VEGF) agents can substantially reduce loss of vision. Since timely application of such treatments is substantial to make a difference in prognostic processes, the goal of retinopathy screening is the timely detection of retinopathy that would, without intervention, cause vision loss...
November 1, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/29077188/aflibercept-in-the-treatment-of-diabetic-macular-edema-a-review-and-consensus-paper
#18
Teresio Avitabile, Claudio Azzolini, Francesco Bandello, Francesco Boscia, Sandro De Falco, Diego Fornasari, Paolo Lanzetta, Leonardo Mastropasqua, Edoardo Midena, Federico Ricci, Giovanni Staurenghi, Monica Varano
PURPOSE: To reach a consensus, among experts, on the role of aflibercept in diabetic macular edema (DME) through literature review. METHODS: Two round tables, involving 12 Italian experts, were organized: in the first one, 6 pharmacologic and clinical questions were selected and analyzed by a systematic literature review, using a population, intervention, control, and outcomes framework; in the second one, the nominal group technique was used to discuss relevant evidence related to each question...
October 14, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/29076303/anti-vegf-therapy-for-diabetic-eye-diseases
#19
Bobak Bahrami, Thomas Hong, Mark C Gilles, Andrew Chang
Diabetic retinopathy (DR) is a leading cause of vision impairment and blindness in the working-age population. The identification of vascular endothelial growth factor (VEGF) as a key mediator in the pathogenesis of DR has revolutionized the management of this vision-threatening disease. There is now strong evidence supporting intravitreal anti-VEGF therapy as first line in the management of sight-threatening diabetic macular edema (DME), along with a growing body of evidence to support the use of anti-VEGF drugs for proliferative DR...
November 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/29069705/-the-impact-of-multiple-intravitreal-anti-vegf-injections-on-intraocular-pressure
#20
Ioannis Lamprakis, Margarita Georgieva Todorova, Matthias Grüb, Torsten Schlote
Background To evaluate the possible effects of multiple intravitreal anti-vascular endothelial growth factor (VEGF) injections on intraocular pressure (IOP). Methods This study included 50 eyes of 50 patients who underwent multiple (≥ 10 injections) intravitreal anti-VEGF injections in one eye with age-related macular degeneration, diabetic macular edema or retinal vein occlusion. IOP was recorded after every injection on the first postoperative day. IOP > 21 mmHg was regarded as abnormal. For statistical analysis, the IOP was correlated with the number of injections...
October 25, 2017: Klinische Monatsblätter Für Augenheilkunde
keyword
keyword
36615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"